EYE Summary (August 2024): Incredibly Undervalued, page-235

Spot on. The results are in. The company has increased its sales, which is great, but expenses related to the sales have accelerated more, it raised capital only in March and by now will be showing signs of depleting it. That capital was to advance the sales of the prime product, meanwhile the holy grail - 2RT sits on a shelf with a patent and no money to develop it or get it past trials. The gains have been had - harsh but true. And that is best case if there is no market correction in the meantime...........there will be at some point.